Correlation Between C4 Therapeutics and Veracyte

Can any of the company-specific risk be diversified away by investing in both C4 Therapeutics and Veracyte at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining C4 Therapeutics and Veracyte into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between C4 Therapeutics and Veracyte, you can compare the effects of market volatilities on C4 Therapeutics and Veracyte and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in C4 Therapeutics with a short position of Veracyte. Check out your portfolio center. Please also check ongoing floating volatility patterns of C4 Therapeutics and Veracyte.

Diversification Opportunities for C4 Therapeutics and Veracyte

-0.54

Correlation Coefficient

C4 Therapeutics  Veracyte

Excellent diversification

The 3 months correlation between CCCC and Veracyte is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding C4 Therapeutics and Veracyte in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Veracyte and C4 Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on C4 Therapeutics are associated (or correlated) with Veracyte. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Veracyte has no effect on the direction of C4 Therapeutics i.e., C4 Therapeutics and Veracyte go up and down completely randomly.

Pair Corralation between C4 Therapeutics and Veracyte

Given the investment horizon of 90 days C4 Therapeutics is expected to generate 2.77 times more return on investment than Veracyte. However, C4 Therapeutics is 2.77 times more volatile than Veracyte. It trades about 0.1 of its potential returns per unit of risk. Veracyte is currently generating about -0.13 per unit of risk. If you would invest  163.00  in C4 Therapeutics on May 1, 2025 and sell it today you would earn a total of  53.00  from holding C4 Therapeutics or generate 32.52% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

C4 Therapeutics  vs.  Veracyte

C4 Therapeutics

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in C4 Therapeutics are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. In spite of rather weak fundamental indicators, C4 Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point.

Veracyte

Risk-Adjusted Performance

Very Weak

Over the last 90 days Veracyte has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in August 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors.

Pair Trading with C4 Therapeutics and Veracyte

The main advantage of trading using opposite C4 Therapeutics and Veracyte positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if C4 Therapeutics position performs unexpectedly, Veracyte can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Veracyte will offset losses from the drop in Veracyte's long position.

The idea behind C4 Therapeutics and Veracyte pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.